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Background: The structures of the mesentery including adipose tissue, nerves, and lymphatics play an important
role in the pathogenesis and disease progression of Crohn’s disease (CD). Conventional surgical resection for CD
usually does not involve resecting the mesentery en bloc with the specimen. This contrasts with complete mesocolic
excision (CME) in colorectal cancer, which involves radical resection of the mesentery. Preliminary evidence from smaller
studies suggests that applying the principle of mesocolic excision to CD surgery may reduce the risk of postoperative
recurrence. This randomized controlled trial is designed to test whether applying the principles of mesocolic excision to
CD results in reduced postoperative recurrence. It also aims to evaluate intra- and postoperative morbidity between the
two approaches.
Methods: This international, multicenter, randomized controlled trial will randomize patients (n = 116) scheduled to
undergo primary ileocolic resection to either receive extensive mesenteric excision (EME) or conventional ileocolic
resection with limited mesenteric excision (LME). Five sites will recruit patients in three countries. In the EME group, the
mesentery is resected following CME, while avoiding the root region, i.e., 1 cm from the root of the ileocolic artery and
vein. In the LME group, the mesentery is retained, i.e., “close shave” or < 3 cm from the border of bowel. The primary end
point will be surgical recurrence after surgery. The secondary end points will be the postoperative endoscopic and clinical
recurrence, and intra- and postoperative morbidity. Demographics, risk factors, laboratory investigations, endoscopy,
postoperative prophylaxis and imaging examination will be assessed. Analysis of the primary outcome will be on an
intention-to-treat basis.
Discussion: If mesocolic excision in CD reduces postoperative disease recurrence and does not increase morbidity, this
trial has the potential to change practice and reduce recurrence of CD after surgical resection.
Trial registration: Clinical Trials.gov, ID: NCT03769922. Registered on February 27, 2019.
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Disease recurrence at the site of the anastomosis after
ileocolic resection for Crohn’s disease (CD) is of pivotal
clinical importance. More than 90% of CD patients de-
velop endoscopic recurrence, 20% of whom are symptom-
atic. Despite developments in biological therapy for CD,
approximately 30–40% of patients require reoperation
within the first 5 to 10 years. In addition to environmental
factors, such as smoking and diet, the clinical pattern of
disease, e.g., stricturing versus fistulating behavior, and
pathological features of the resection margin, may also in-
fluence the risk of postoperative recurrence [1, 2].
Abnormal changes in the mesentery in patients with
CD have been noted for several decades. Emerging data
suggest that the mesenteric tissue plays an important
role in the pathogenesis of CD [3–5]. A high value of
visceral fat content [6], an increased mesenteric
lymphatic-vessel density in the resection margin [7], and
the presence of granulomata in the mesenteric lymph
nodes have been found to be associated with postopera-
tive recurrence [8].
Conventional surgical resection for CD does not usu-
ally involve resection of the associated mesentery, with
traditional teaching advocating staying “close to the
bowel wall.” To date, the inclusion of the mesentery in
intestinal resection for CD has not become standard
practice. This is largely due to technical concerns re-
garding risk of bleeding when handling tissues with sig-
nificant inflammation, e.g., disease-related perforation,
fistula formation, adhesions, and thickened mesentery
[9, 10], which could lead to hematomas, ongoing
hemorrhage, and injury to the mesenteric root [11, 12].
Therefore, despite recent interest in the role of the mes-
entery in CD, the implication of resection of the mesen-
tery along with the diseased bowel has not been
evaluated.
Our preliminary data indicate that: (1) extensive
mesenteric excision is safe and feasible in surgical re-
section for CD; (2) inclusion of mesentery resection
does not cause specific morbidity; and (3) extensive
mesenteric excision results in reduced incidence of
endoscopic recurrence after surgery (unpublished
data). In addition, Coffey et al. reported that the in-
clusion of the mesentery in the course of ileocolic re-
section for CD is associated with reduced recurrence
requiring reoperation [9].
To date, there has been no prospective trial comparing
wide mesocolic resection with conventional surgery in
CD. Thus, the objective of this multicenter, single-blind,
randomized controlled trial is to determine whether
there is a reduction in the rate of postoperative recur-
rence of CD following extensive mesenteric excision
(EME), when compared to that of conventional limited
mesenteric excision (LME) for ileocolic disease.Methods
Study population
Patients with CD limited to the distal ileum and/or right
colon receiving their index ileocolic resection are eligible
for inclusion. Eligibility criteria include: age between 18
and 65 years with a documented history of CD based on
endoscopic, radiological, or histological criteria. The ex-
clusion criteria are: pregnancy or planning to become
pregnant in the following year; CD located at a gastro-
intestinal site other than the terminal ileal cecum, or
right colon; and intestinal fistula requiring resection of
another segment of bowel. Eligible patients with perianal
disease will be included. All participants will provide
written informed consent. The schedule of enrollment,
interventions, and assessment is presented in Fig. 1 (see
also Additional file 1: Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) Checklist
LME EME).Randomization
Given the nature of surgical procedures, it is not pos-
sible to blind the surgical team to the assigned treatment
arm. However, patients will be blinded to the type of
mesenteric excision performed. Eligible patients enrolled
by each participating center will be randomized based
on a computer-generated list maintained centrally. The
randomization codes are uploaded on Google docs, and
the study co-ordinator at each center will receive a link
to the codes.. The group allocation will be conducted by
a staff surgeon, or research assistant who is blind to the
study by a sealed, opaque envelope. Individuals other
than the surgical team involved in the trial will be blind
to the assigned treatment arm according to the blinding
guidelines indicated by Probst et al. [13].
After entering the abdomen, the surgeon will deter-
mine whether a hemostatic division of the mesentery is
technically possible. If this is the case, as we would ex-
pect in the majority of patients, the envelope containing
the randomization can be opened to find out what group
the patient has been randomized to, and the operation
proceeds as per the group allocation to either a
mesenteric-based resection or conventional resection. If
mesenteric division is not deemed possible, the patient
will be excluded from the trial. The reasons for those
that have not been randomized would be clearly re-
ported. The number of excluded patient will be separ-
ately recorded. Alternatively, the patient may undergo
initial stoma diversion followed by delayed resection
with preoperative re-randomization in 6 months. This
approach will be left to the discretion of the operating
surgeon, while the reason for stoma creation should be
documented. Patients undergoing delayed resection are,
therefore, eligible for inclusion in the study.
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Flow Diagram of schedule of enrollment, interventions,
and assessments
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Depending on patient and surgeon preference, surgery
will be performed laparoscopically or open. Ileocolic
mesenteric mobilization and hemostatic division of the
mesentery will be performed as reported [9]. In a con-
ventional limited resection, the mesentery is resected
within 3 cm from the bowel, leaving most of the mesen-
tery in situ. In the extensive mesenteric resection group,
a mesocolic resection is performed while avoiding the
root region by dividing the mesentery 1 cm from the
root of ileocolic artery and vein. The proximal mesen-
teric incision will be made just proximal to the mesen-
teric transition zone [9], while the distal incision will be
placed where both the mesentery and intestine are
macroscopically normal immediately distal to the region
of disease. After resection, an ileocolic anastomosis will
be then performed. The type of anastomosis construc-
tion and the anastomotic configuration are based on the
individual surgeon’s preference.
We expect that the majority of patients should be
treated with ileocolic resection and primary anastomosis.
However, in selected cases the surgeon may elect to re-
route the fecal stream away from an anastomosis with
proximal stoma diversion based on the surgeons’ clinical
judgment and intra-operative findings. The reasons for
stoma diversion should be clearly documented. If a cover-
ing loop-ileostomy is fashioned then it is recommendedthat this be reversed (if feasible) after 3months and that
the time of ileocolic resection and ileostomy be considered
as the starting point of postoperative surveillance. How-
ever, the date of reversal will also be recorded as it is pos-
sible that recurrence will differ in those patients who
undergo diversion compared to those who are not.
Postoperative examination of the resection specimen
The mesentery will be inspected and morphological fea-
tures of mesenteric disease will be recorded. Mesenteric
and mucosal disease scores will be documented [9]. For
histopathological assessment, each specimen will be ex-
amined at two levels, intestinal and mesenteric. Each will
be examined at a number of points along the longitu-
dinal axis of the intestine [9].
Maintenance therapy
Prophylactic treatment is recommended after ileocolic
intestinal resection in patients with at least one risk fac-
tor for recurrence (Table 1) [14]. For those developing
endoscopic recurrence or clinical recurrence after sur-
gery, management will be undertaken in keeping with
local gastroenterology standard practice and guidelines.
End points
In total, patients will be followed for 5 years after sur-
gery. The primary end point of the study is postoperative
Table 1 Predictors of early postoperative recurrence after
ileocolonic resection
Risk factor Level of evidence
Smoking EL1
Prior intestinal surgery EL1
Penetrating disease at index surgery EL2
Perianal location EL2
Granulomata in resection specimen EL2
Myenteric plexitis EL3
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requirement for repeat surgery for a CD-related indica-
tion caused by recurrent disease in the same anatomical
areas. If reoperation is required it should be documented
whether the reason is a specific CD-related complica-
tion, or a complication related to surgery in general (i.e.,
hemorrhage, intraperitoneal collection not amenable to
conservative treatment, wound dehiscence, anastomotic
leakage). CD-related indications for surgery include: (1)
development of symptoms refractory to medical treat-
ment; and (2) development of a complication caused by
CD (i.e., fistula, perforation, and obstruction).
Secondary end points include assessment of endo-
scopic recurrence and clinical recurrence. Endoscopic
recurrence will be assessed using the widely accepted
Rutgeert’s score [15]. Only disease (Rutgeert’s score i2,
or higher) proximal to the anastomosis or in the peria-
nastomotic area is considered to be consistent with
endoscopic recurrence. Disease in other sites will not be
considered to be recurrence. Clinical recurrence is de-
fined as the presence of endoscopic disease or radio-
logical evidence plus the presence of symptoms
attributable to CD that are severe enough to require
medical or surgical treatment.
In addition, intra-operative complications and 30-day
postoperative outcomes will be evaluated. These include
estimated blood loss, duration of surgery, postoperative
morbidity, reoperation rate, and the length of postopera-
tive hospital stay. Postoperative complications will be re-
corded and classified based on the Clavien-Dindo
classification [16].
Follow-up
Postoperative reviews will be conducted at 6-monthly in-
tervals at which point patients will have a full clinical,
endoscopic, and radiological assessment. The CD Activ-
ity Index [17] will be also recorded at each visit. If indi-
viduals experience symptoms suggestive of recurrent CD
prior to the scheduled colonoscopy, they will undergo a
colonoscopy and other investigations as deemed appro-
priate by their own gastroenterologist or surgeon to as-
certain whether they have recurrent disease. If
endoscopic or clinical recurrence are demonstrated, thepatient should undergo continued follow-up if, or until,
they develop recurrence requiring surgery. If patients do
develop surgical recurrence, their participation in the
study is terminated as they are considered to have
reached the primary and ultimate end point.
Sample size
There are no registered or published randomized con-
trolled trials (RCTs) comparing limited with extensive
mesenteric resection in patients with CD. Our sample
size calculation is based on the surgical recurrence in a
retrospective study reported by Coffey et al. [9]. It is esti-
mated that 30% of subjects undergoing an ileocolonic
anastomosis with conventional limited mesenteric exci-
sion would develop surgical recurrence at 60 months
after surgery. To detect a 20% decrease in the surgical
recurrence rate after wide mesenteric excision with 80%
power and 5% significance, a total of 100 patients must
be recruited. The sample size is adjusted to 116 to allow
for a 10% loss to follow-up and 5% anastomotic leak.
Statistical analysis
Data will be presented as median (range), mean, and
standard deviation for continuous variables, and percent-
ages for categorical and ordinal data. In order to test
whether there are differences between the two groups in
the reduction of the primary and secondary outcome,
Student’s t tests will be performed for continuous vari-
ables and chi-square or Fisher’s exact test for categorical
variables. Those variables in which statistically signifi-
cant differences are found will be introduced in the ana-
lyses as covariates. Kaplan-Meier analysis with log-rank
statistics will be used to assess event-free interval and
Cox forward conditional proportional hazards for regres-
sion analysis. We plan intention-to-treat analysis of the
primary outcome. The full analysis set and per-protocol
set will be used for the assessment of efficacy. Interim
analyses will be done annually for the first 5 years after
index surgery, and the sample size would be adjusted ac-
cordingly. An interim analyses will be performed to see
if the trial should be continued or stopped, and so it
serves as a safeguard. If the outcomes are very poor,
more than would be expected, a clear-cut trend towards
increased severe morbidity (classed as Clavien-Dindo
grade 3 or greater) in relation to either the control or
test group, the trial would be stopped and the enrolled
participants would have been followed for outcomes and
the primary analysis would have focused on the mortal-
ity end point. Alternatively, if there was a clear differ-
ence between the two groups in terms of benefits for the
test cohort, with statistically significant findings emer-
ging on comparison of one group over another that sup-
port uncontestable differences between groups, then it
might also be stopped and all enrolled participants will
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focus on the efficacy end point. Data will be monitored by
the treating clinicians and external independent trial mon-
itoring committee, and the principle investigator of each
participative site will take overall responsibility. An exter-
nal independent trial monitoring committee will also
analyze interim anonymized outcome data. All analyses
considered a P value of ≤ 0.05 as statistically significant.
Cessation of trial
The trial will stop in three circumstances: (1) once 5 years
after first enrollment has been reached; (2) statistically sig-
nificant findings emerge on comparison of one group over
another that support uncontestable differences between
groups; and (3) a clear-cut trend is demonstrated toward
increasingly severe morbidity (classified as Clavien-Dindo
grade 3 or greater) in either treatment arm.
Discussion
This randomized clinical trial should provide evidence
on the effectiveness of extensive mesenteric excision on
the recurrence of CD. Our hypothesis is that the inclu-
sion of the mesentery during resection of bowel leads to
improvement in the natural history of CD. The primary
end point is postoperative surgical recurrence, which is a
relatively objective outcome. In addition, endoscopic re-
currence and clinical recurrence after surgery, which are
associated with reoperation for recurrent CD, will be
also evaluated. Given that CD includes a thickened mes-
entery, which can prevent vessel-sealing devices from
achieving adequate hemostasis [18], care will be taken to
use previously described techniques for safe division of
the mesentery [9].
Previous studies of CD have primarily focused on
changes within the intestinal wall associated with the dis-
ease and on the accompanying inflammatory processes in
the mucosa and submucosa. Wide resection of the mar-
gins of macroscopically normal bowel to ensure clearance
of all macroscopic, and possibly microscopic bowel dis-
ease, does not lead to a decrease in postoperative recur-
rence [19–21]. Mesenteric tissue, which includes fat,
lymphatics, vessels, and nerves, is not considered as a “by-
stander” in CD [3, 22–24]. We recently reported that the
increased visceral fat area is an independent risk factor of
postoperative disease recurrence in patients with CD [6].
This has been confirmed by a separate study in another
ethnic population [25]. This may be partly explained by
the findings that increased mesenteric adipose tissue is as-
sociated with complex disease status [26], elevated inflam-
matory markers, bowel-wall thickening [27, 28], and
transmural inflammation [29]. In addition to mesenteric
fat, lymphatic alterations, such as increased mesenteric
lymphatic-vessel density, are also associated with postop-
erative disease recurrence [7, 30]. Additionally, bacterialtranslocation to mesenteric adipocytes and to the
mesenteric lymph nodes are common in patients with
CD [22], which may lead to an increased production
of proinflammatory cytokines and result in perpetual
inflamed mesenteric and intestinal inflammation. The
cross-talk among stromal cells. such as pre-
adipocytes, endothelial cells, fibroblasts, and immune
cells, including T-cells and macrophages, suggest that
the mesentery play a pivotal role in the disease course
of CD [3, 4, 31–33]. These may at least in part, ex-
plain the results that mesentery-based surgery is asso-
ciated with decreased postoperative recurrence.
The assessment of surgical factors including hand-sewn
or stapled anastomosis, and extensive versus limited intes-
tinal resection have failed to demonstrate any benefit in
preventing postoperative recurrence in patients with CD.
However, extensive mesenteric resection appears to confer
a benefit in smaller studies. Since mesenteric and mucosal
abnormalities develop in tandem, we consider the mesen-
tery transition point as the landmark for intestinal division
in the mesocolic-resection approach, thereby reducing the
otherwise troublesome bleeding typically encountered
when dividing the acutely inflamed mesentery [34]. Focus-
ing on the mesentery, in addition to intestine, may offer a
new surgical approach for CD [35]. An anticipated chal-
lenge of this trial is the concern that a wide mesenteric re-
section could lead to hematomas and hemorrhage,
particularly in an extremely hostile intra-abdominal oper-
ating environment with considerable inflammation, adhe-
sions, and abscess formation [18]. However, both our
preliminary data and the paper by Coffey et al. indicate
that the inclusion of the mesentery during ileocolonic re-
section is safe [5]. Indeed, a safe technique for division of
the mesentery is outlined as part of the trial [9], the root
of the mesentery will be avoided and the trial participants
monitored closely for any increase in complications with
this approach.
If the inclusion of the mesentery in ileocolic resection
confers a benefit in reducing postoperative recurrence, a
mesentery-based approach may become the new stand-
ard for surgical resection of CD.
Trial status
The protocol reported here is version 1.2, dated 30 Oc-
tober 2018. Trial enrollment began on 1 February 2019
and is anticipated to finish on 31 December 2020.Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-4105-x.
Additional file 1. Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents; LME EME.
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